Europe Glp-1 Receptor Agonist Market Size & Outlook
Europe glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Europe glp-1 receptor agonist market highlights
- The Europe glp-1 receptor agonist market generated a revenue of USD 4,287.4 million in 2023.
- The market is expected to grow at a CAGR of 22.4% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Norway is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 4,287.4 million |
| Market revenue in 2030 | USD 17,668.7 million |
| Growth rate | 22.4% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Europe region accounted for 11.7% of the global glp-1 receptor agonist market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 139,127.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 43.66% in 2023. Horizon Databook has segmented the Europe glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, mounjaro (tirzepatide), wegovy (semaglutide), rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
lucrative CAGR over the forecast period. This growth can be attributed to increased research funding and the presence of key market players in the region. In addition, rising investments are driving the number of biopharmaceutical companies in Europe.
The market for GLP-1 receptor agonists in Europe is experiencing significant growth, driven by an increasing prevalence of type 2 diabetes and a growing focus on obesity management. With diabetes affecting approximately 10% of the European adult population and obesity rates on the rise, the demand for effective treatments is expanding.
GLP-1 receptor agonists, known for their ability to improve glycemic control and support weight loss, are becoming a preferred choice among both healthcare providers and patients across the region. Furthermore, the market is experiencing a notable surge in demand due to various factors; for instance, in July 2024, the European drug authorities announced recommendations to address the growing shortages in GLP-1 receptor agonists.
Reasons to subscribe to Europe glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe glp-1 receptor agonist market , including forecasts for subscribers. This continent databook contains high-level insights into Europe glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe glp-1 receptor agonist market size, by country, 2018-2030 (US$M)
Europe GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
